HBIO Harvard Bioscience Inc. Forecast, Technical & Fundamental Analysis

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HBIO just turned positive on October 06, 2026. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in 40 of 54 cases over the following month. The odds of a continued upward trend are 74%.

Following a +2.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in 164 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

The Aroon Indicator entered an Uptrend today. In 72 of 96 cases where HBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

HBIO broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.897) is normal, around the industry mean (5.020). HBIO has a moderately high P/E Ratio (602.130) as compared to the industry average of (166.342). HBIO's Projected Growth (PEG Ratio) (14.400) is slightly higher than the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.